메틸페니데이트 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "메틸페니데이트" in Korean language version.

refsWebsite

Global rank Korean rank

10nih.gov

4^th place

5doi.org

2^nd place

3^rd place

2drugs.com

399^th place

141^st place

1web.archive.org

1^st place

1neuropsychiatryreviews.com

low place

1archive.today

14^th place

15^th place

1hta.ac.uk

low place

1naver.com

46^th place

2^nd place

archive.today

King S, Griffin S, Hodges Z; 외. (2006). “A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents”. 《Health Technol Assess》 10 (23): iii–iv, xiii–146. PMID 16796929. 2012년 8월 2일에 원본 문서에서 보존된 문서. 2008년 11월 21일에 확인함.

doi.org

dx.doi.org

Kimko, HC; Cross, JT; Abernethy, DR (December 1999). “Pharmacokinetics and clinical effectiveness of methylphenidate.”. 《Clinical Pharmacokinetics》 37 (6): 457–70. doi:10.2165/00003088-199937060-00002. PMID 10628897.
Markowitz JS, Logan BK, Diamond F, Patrick KS (1999). “Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion”. 《Journal of Clinical Psychopharmacology》 19 (4): 362–6. doi:10.1097/00004714-199908000-00013. PMID 10440465. CS1 관리 - 여러 이름 (링크)
Huang YS, Tsai MH (July 2011). “Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge”. 《CNS Drugs》 25 (7): 539–554. doi:10.2165/11589380-000000000-00000. PMID 21699268.
Zhu J, Reith ME (2008). “Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse”. 《CNS & Neurological Disorders Drug Targets》 7 (5): 393–409. doi:10.2174/187152708786927877. PMC 3133725. PMID 19128199.
Volkow ND, Swanson JM (2003). “Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD”. 《The American Journal of Psychiatry》 160 (11): 1909–18. doi:10.1176/appi.ajp.160.11.1909. PMID 14594733.

drugs.com

“Methylphenidate Hydrochloride Monograph for Professionals”. 《Drugs.com》 (영어). AHFS. 2018년 12월 19일에 확인함.
– Ritalin Side Effects. Drugs.com. Retrieved on 2011-10-16.

hta.ac.uk

King S, Griffin S, Hodges Z; 외. (2006). “A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents”. 《Health Technol Assess》 10 (23): iii–iv, xiii–146. PMID 16796929. 2012년 8월 2일에 원본 문서에서 보존된 문서. 2008년 11월 21일에 확인함.

naver.com

news.naver.com

https://news.naver.com/main/read.nhn?mode=LSD&mid=sec&sid1=102&oid=057&aid=0000124244

neuropsychiatryreviews.com

Peter Doskoch (2002). “Why isn't methylphenidate more addictive?”. 《NeuroPsychiatry Rev.》 3 (1): 19. 2009년 3월 30일에 원본 문서에서 보존된 문서. 2011년 10월 22일에 확인함.

nih.gov

ncbi.nlm.nih.gov

Kimko, HC; Cross, JT; Abernethy, DR (December 1999). “Pharmacokinetics and clinical effectiveness of methylphenidate.”. 《Clinical Pharmacokinetics》 37 (6): 457–70. doi:10.2165/00003088-199937060-00002. PMID 10628897.
Markowitz JS, Logan BK, Diamond F, Patrick KS (1999). “Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion”. 《Journal of Clinical Psychopharmacology》 19 (4): 362–6. doi:10.1097/00004714-199908000-00013. PMID 10440465. CS1 관리 - 여러 이름 (링크)
Huang YS, Tsai MH (July 2011). “Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge”. 《CNS Drugs》 25 (7): 539–554. doi:10.2165/11589380-000000000-00000. PMID 21699268.
Gordon N (1999). “Attention deficit hyperactivity disorder: possible causes and treatment”. 《Int. J. Clin. Pract.》 53 (7): 524–8. PMID 10692738.
King S, Griffin S, Hodges Z; 외. (2006). “A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents”. 《Health Technol Assess》 10 (23): iii–iv, xiii–146. PMID 16796929. 2012년 8월 2일에 원본 문서에서 보존된 문서. 2008년 11월 21일에 확인함.
Gonzalez de Dios J, Cardó E, Servera M (2006). “[Methylphenidate in the treatment of attention-deficit/hyperactivity disorder: are we achieving an adequate clinical practice?]”. 《Rev Neurol》 (스페인어) 43 (12): 705–14. PMID 17160919. CS1 관리 - 여러 이름 (링크)
Jaanus SD (1992). “Ocular side-effects of selected systemic drugs”. 《Optom Clin》 2 (4): 73–96. PMID 1363080.
Zhu J, Reith ME (2008). “Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse”. 《CNS & Neurological Disorders Drug Targets》 7 (5): 393–409. doi:10.2174/187152708786927877. PMC 3133725. PMID 19128199.
Volkow ND, Swanson JM (2003). “Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD”. 《The American Journal of Psychiatry》 160 (11): 1909–18. doi:10.1176/appi.ajp.160.11.1909. PMID 14594733.

pubchem.ncbi.nlm.nih.gov

〈Chemical and Physical Properties〉. 《Methylphenidate》. 《Pubchem Compound》. National Center for Biotechnology Information.

web.archive.org

Peter Doskoch (2002). “Why isn't methylphenidate more addictive?”. 《NeuroPsychiatry Rev.》 3 (1): 19. 2009년 3월 30일에 원본 문서에서 보존된 문서. 2011년 10월 22일에 확인함.